We are building the most advanced drug discovery genomics platform for the treatment and continual improvement of skin diseases and health. Our proprietary microbiome-based approach to skin therapy leverages the power of beneficial bacteria on the skin to eliminate harmful bacteria and restore skin to a healthy state. We have successfully completed a phase IB in acne demonstrating both safety and early trends in efficacy.
Our lead program aims to revolutionize the treatment of acne by introducing the first human skin-derived probiotic therapy. Our product roadmap includes additional skin microbiome treatment indications including eczema, psoriasis, rosacea and seborrheic dermatitis.